Skip to main
CORT

Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics (CORT) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 0%
Sell 20%
Strong Sell 0%

Bulls say

Corcept Therapeutics is expected to have a positive outlook due to its recent resubmission announcement and potential second approval for relacorilant by YE 2026, with projected sales for its current medication, Korlym, expected to start in 2Q26 and grow to $1.6B in 2034. The company has also reported strong financial results and a successful pharmacy transition, and its recent launch of Lifyorli has shown positive early launch signals, which could lead to increased revenue guidance and a potential multi-product franchise in oncology and ALS. However, risks to this positive outlook include potential delays or challenges in commercialization, clinical and regulatory issues, and competition within the industry.

Bears say

Corcept Therapeutics is expected to perform well in the long term, as evidenced by a Buy rating and a 12-month price target of $95 from an NPV analysis, EV/sales analysis, and EV/earnings analysis. However, there are several risks that could hinder the company's growth, including commercial, clinical and regulatory, reimbursement, financial, legal, and intellectual property risks. Investors should keep a close eye on these risks when considering an investment in Corcept Therapeutics.

Corcept Therapeutics (CORT) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corcept Therapeutics (CORT) Forecast

Analysts have given Corcept Therapeutics (CORT) a Buy based on their latest research and market trends.

According to 5 analysts, Corcept Therapeutics (CORT) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $122.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $122.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corcept Therapeutics (CORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.